


The p53 tumor suppressor


GSK Lecture
March 16, 2026

p53 mutations in human cancers




- p53 mutations are the most frequent event in human cancer
- Mutations can occur throughout the open reading frame

p53 mutations in human cancers



Features of p53 mutant tumors




- More aggressive histopathology and increased invasion
- Highly rearranged genomes
- Typically linked to poor patient prognosis
- Frequent in tumors with limited treatment options
- Often linked to poor therapy response


Challenges in navigating p53 research

- p53 is a highly studied gene
- ~ 130,000 papers published with the term 'p53' in the abstract ('chromatin' ~ 143,000)
- More information has not achieved clarity
- We still do not understand why p53 is so important in cancer nor its role (if any) in normal physiology

Publications with *p53* or *TP53* in the abstract (PubMed)



Publications on major cancer genes per year



Decade 1

The discovery of p53 and its oncogenic role

DNA tumor viruses

- RNA tumor viruses inadvertently pick up cellular DNA and were essential for the identification of oncogenes
- Tumor viruses a tool to unlock molecular events linked to oncogenic “transformation”
- DNA tumor viruses occasionally integrate into the host genome leading to transformation
- DNATV oncoprotein were used to identify cellular processes linked to transformation



Discovery of p53




David Lane




Arnold Levine

Discovery of p53




- David Lane and Arnold Levine were independently studying SV40 t antigen and noticed it bound a 53kD cellular protein
- Protein was highly expressed in SV40 transformed cells
- Hypothesized it might mediate action of T Ag on transformation (i.e. pro-oncogenic)

p53 has properties of an oncogene



- p53 protein is highly expressed in certain cancers
- Microinjection of antibodies against p53 protein triggers proliferative arrest


p53 has properties of an oncogene



- p53 protein is highly expressed in certain cancers
- Microinjection of antibodies against p53 protein triggers proliferative arrest
- A cloned p53 cDNA facilitates immortalization of primary fibroblasts and cooperates with oncogenic was to transform


Emerging inconsistencies in oncogenic role

- Friend murine leukemia virus thought to promote cancer through insertional mutagenesis
- Some leukemia harbored integrations with two integrations in the p53 gene
- The dogma of “oncogenes” prevented a full understanding of the potential implications




p53 is a tumor suppressor gene

- Different p53 cDNA clones have different sequences
- Different clones had different behaviors in cellular transformation assays
- So-called 'wild-type' clones inhibited proliferation and could suppress transformation (Oren and Levine)




p53 is a tumor suppressor gene

- Different cloned p53 cDNAs and different sequences
- Different clones had different behaviors in cell transformation assays
- So-called 'wild-type' clones inhibited proliferation and could suppress transformation (Oren and Levine)
- Apparent loss of function mutations observed at high frequency in human cancers (Vogelstein)



What went wrong?

- TAg actively counters p53 stabilization to prevent proliferative arrest
- p53 mutations in tumors are dysfunctional but stabilized owing to lack of degradation
- PAb421 anti-p53 antibody changes p53 conformation to an active form
- Initial p53 cDNAs obtained from cancer cells
- p53 functions as a tetramer and mutant proteins can function as dominant negatives when expressed at high levels




Decade 2

p53 activity and regulation

Li-Fraumeni syndrome linked to p53

- Li-Fraumeni is an autosomal dominant familial cancer syndrome characterized by early onset cancer (soft tissue sarcoma, breast, other)
- A substantial subset of patients have p53 mutations
- Tumors display 'loss of heterozygosity' at the p53 locus



B

ID	Age in 2014	Tumors
I:1	Deceased	Liver mass at 46 y
II:1	40 y	None
II:2	Deceased	Breast cancer at 32 y
II:3	35 y	None
II:4	35 y	Breast cancer at 34 y
II:5	30 y	None
III:1	13 y	Adrenal pheochromocytoma at 3 y, and kidney cyst at 12 y
III:2	10 y	None
III:3	6 y	No
III:4	5 y	Medulloblastoma at 5 y
III:5	3 y	Choroid plexus papilloma at 3 y

p53 mutations linked to carcinogens

- The high frequency of p53 mutations lent itself to the study of mutational signatures/mechanisms early on.
- Different tumor types display different types of mutations at the gene level (Curt Harris, others)
- Often these could be traced to carcinogenic factors pre-disposing to cancer (aflatoxin, UV, cigarette smoke)




Figure 4. Distribution of p53 mutations in various types of cancers. (a) Schematic diagram of p53. Human p53 consists of 393 amino acids with five evolutionarily conserved domains (I-V). Domains II-V correspond to the DNA-binding domain, which is the target for p53 mutations^{25,26}. (b) In each type of cancer surveyed, mutations are scattered in this central region, although a hot-spot exists at codons 175, 248 and 273. The only exception is hepatocellular carcinoma, which shows a mutational hot-spot at codon 249 (data for hepatocellular carcinoma also include cancers from countries not exposed to aflatoxin B1).

p53 knockout mouse develops tumors

- p53 constitutive knockout mice develop normally
- Mice highly predisposed to tumors (mainly thymic lymphoma and certain sarcomas)
- p53^{+/-} develop tumors at a longer latency of typically lose the remaining wild-type p53 allele
- Superficially, p53 functions as a 'pure' tumor suppressor

nature 19 March 1992

Article

Nature 356, 215 - 221 (1992); doi:10.1038/356215a0



Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Lawrence A. Donehower, Michele Harvey, Betty L. Slagle, Mark J. McArthur, Charles A. Montgomery, Janet S. Butel, Allan Bradley

Mutations in the p53 tumour-suppressor gene are the most frequently observed genetic lesions in human cancers. To investigate the role of the p53 gene in mammalian development and tumorigenesis, a null mutation was introduced into the gene by homologous recombination in murine embryonic stem cells. Mice homozygous for the null allele appear normal but are prone to the spontaneous development of a variety of neoplasms by 6 months of age. These observations indicate that a normal p53 gene is dispensable for embryonic development, that its absence predisposes the animal to neoplastic disease, and that an oncogenic mutant form of p53 is not obligatory for the genesis of many types of tumours.


p53 as 'the guardian of the genome'

- p53 facilitates cell cycle arrest (G1 checkpoint) following DNA damage (Kastan)
- p53 loss triggers genomic instability (Tlsty, Wahl)
- David Lane coins the phrase 'p53, guardian of the genome'



p53 can promote apoptosis


- p53 over expression promotes apoptosis in leukemia cell line (Oren)
- Studies using p53 knockout mice indicates that p53 promotes apoptosis following DNA damage (but not other stimuli) in thymocytes
- p53 is stabilized by certain oncogenes, which promote apoptosis



Lowé Nature 1993

p53 mutations and chemoresistance

Treatment response of murine lymphomas to cyclophosphamide




Schmitt Cell 2002

- Disruption of p53 apoptotic function reduces killing by radiation and cytotoxic drugs
- Loss of p53 is linked to chemoresistance in vivo
- Some human tumors show clear links between p53 mutation and therapy resistance, though whether it is due to an apoptotic defect remains unclear
- **NEW IDEA: genotype of cancer cell dictates treatment outcome**

p53 is a transcription factor


- p53 has transcriptional activation capabilities
- p53 is a sequence specific DNA binding protein
- Crystal structure of the core domain suggests mutations disrupt this activity



Nikola Pavletich (MSK)


p53 is a transcription factor

- p53 has transcriptional activation capabilities
- p53 is a sequence specific DNA binding protein
- Crystal structure of the core domain suggests mutations disrupt this activity
- The biochemical function of p53 as a transcription factor appears important for its tumor suppressive role



Peter Chumkov


Negative regulation of p53 via Mdm2



JC Marine and G Lozano

- 'Murine double minute 2' (aka Mdm2) is amplified in murine and human cancers
- Mdm2/Hdm2 protein degrades p53
- p53 is phosphorylated by the DNA damage kinase ATM which disrupts Mdm2-mediated degradation
- Mdm2 is a p53 target gene
- Mdm2 functions in a feedback mechanism to blunt p53 activity
- Mutant p53 proteins do not induce Mdm2 and thus are stabilized

ARF and oncogene signaling to p53




Charles Sherr (St. Jude)

- Chromosome 9 deletions frequently occur in human cancers
- The locus encodes (at least) two tumor suppressors - p16 and ARF - that have an unusual organization
- ARF inhibits Mdm2 interactions with p53 (DePinho, Sherr, others)
- ARF is not induced by DNA damage but is by oncogenes (Sherr)
- ARF is required for oncogene induced apoptosis and senescence (Sherr, Serrano, Lowe, Vousden)


p53 is a member of a gene family

- p53 is a member of a gene family that includes p63 and p73
- p63 and p73 KO have developmental phenotypes
- p63 and p73 have splice variants that influence function (TA and DN)
- Re-evaluation of p53 indicates it also has splice variants of unclear function
- Neither p63 or p73 are potent tumor suppressors



Textbook view of p53

- p53 is a transcription factor that can be activated by cellular stress to drive distinct anti proliferative processes
- p53 activity is regulated upstream by DNA damage or ARF which prevent Mdm2 inhibition and stabilize p53
- p53 mutations disable transcription functions allowing aberrant proliferation
- p53 regulators are also mutated in cancer




Charles Sherr Nat Rev Cancer

Decade 3


New p53 biology and emerging confusion

p53 and organismal aging

- A fortuitously engineered p53 mutant mouse has p53 hyper activation and displays premature aging (Donehower)
- Suggests that too much of p53 is a bad thing
- Mice with an extra copy of wt p53 ('super p53 mice') are cancer resistant but do not show aging phenotypes (Serrano)




Hot topic: p53 regulates microRNAs



- microRNAs can be direct transcriptional targets of p53 (Hannon, Ventura)
- Induction of mir34 family is linked to repression of genes involved in cell cycle arrest
- Provides one mechanism for how p53 represses gene expression


Hot topic: p53 and stem cell biology



- p53 restricts the ability of Yamanaka factors to produce induced pluripotent stem cells (5 Nature papers)
- Loss of p53 increases iPS frequency ~100 fold
- Senescence is a p53 output that prevents iPS formation
- Suggests a role for p53 in restricting lineage plasticity but role in cancer undefined.


More sophisticated models expand capabilities

- More sophisticated mouse models allow for tissue specific p53 inactivation together with other oncogenic events
- KP lung cancer model and KPC pancreas cancer models become work horse tools that genetically and histologically model human carcinomas




p53 restoration in tumors

- Mouse models with conditional (inducible) wt p53 alleles are produced
- p53 reactivation triggers tumor regression (Evans, Ventura/Jacks, Lowe)
- Loss of p53 is required to maintain cancer
- Targeting the p53 network would be therapeutically viable




Does p53 have oncogenic activities?




- Mice harboring p53 hotspot mutants develop tumors with a different spectrum than nulls (Jacks, Lozano)
- p53 mutant strains display more metastases
- p53 mutant proteins can have 'gain of function' activities
- Mechanism appears to involve mutant p53 protein binding to p53 family members

Does p53 have oncogenic activities?


(A) Wild-type p53




(B) Dominant negative p53



(C) Loss-of-function p53




(D) Gain-of-function p53



- Mice harboring p53 hotspot mutants develop tumors with a different spectrum than nulls (Jacks, Lozano)
- p53 mutant strains display more metastases
- p53 mutant proteins can have 'gain of function' activities
- Mechanism appears to involve mutant p53 protein binding to p53 family members

Is p53 just a transcription factor, or more?




- p53 can associate with mitochondria and this may be linked to apoptosis (Moll, Green)
- Mitochondrial p53 binds Puma and promotes apoptosis (Green)
- p53 mutants defective in puma binding.... So could it be linked to tumor suppression? (Green)
- No one talks about this anymore...

Decade 4

Increasing confusion yet notable advances

Emerging debate on what's important


- There has been substantial debate regarding which p53 effector functions are most important for tumor suppression
- Studies demonstrate that disruption of key p53 effectors in cell cycle arrest and apoptosis do not form tumors as do p53 null
- Separation of function p53 mutations point to p53 and cancer metabolism or other p53 functions as key
- There are caveats...



Valente Cell Rep 2016


More “gain-of-function” mechanisms identified

- While increased metastasis is the most common p53 ‘gain of function’ output identified, there are many other effects (stem cell biology, cell plasticity, epigenetics)
- Virtually every study reveals a different mechanism underlying the biology
- Even the same mutant allele can have different gain of function activities depending on context
- **How might it work?**




p53 gain of function push back

- Analysis of CRISPR screening data does not reveal a relationship between p53 mutation and p53 mutant dependency in cancer cell lines (Hahn)
- Inactivation of p53 by CRISPR in a range of cancer cell lines has no phenotype (Strasser)
- Precise generation of p53 mutants in AML lines appear strictly dominant negative (Ebert)
- **BUT: analyses have been primarily (though not completely) in vitro**




Binary classification of tumors is simplistic

- p53 mutations show a range of distributions across cancers, including a large number of truncating alleles
- The most common p53 configuration is a missense mutation on one allele and a deletion event that targets the other and a series of adjacent genes
- Different p53 mutations have different biological activities (dominant negative, gain of function) and to different degrees
- Deletion events target haploinsufficient tumor suppressors linked to p53 deletions




A range of p53 mutational configurations

- p53 mutations show a range of distributions across cancers, including a large number of truncating alleles
- The most common p53 configuration is a missense mutation on one allele and a deletion event that targets the other and a series of adjacent genes
- Different p53 mutations have different biological activities (dominant negative, gain of function) and to different degrees
- Deletion events target haploinsufficient tumor suppressors linked to p53 deletions
- The classification of tumors as 'wt' or 'mutant' for p53 is likely simplistic




p53 mutations: not just any instability

p53 mutations and CNA




Giovanni Cirello, et al Nature Genet 2013

p53 mutations and WGD




Bielski et al, Nature Genet 2018

CNA, polyploidy, and p53 mutations in pancreas cancer



New roles for p53


- p53 down regulation enables limb regeneration in salamander and promotes lineage plasticity in cancer (Brockes)
- p53 reactivation can revert tumors to premalignant cell fate (Lowe, Finley)
- p53 linked to clonal hematopoiesis (as is p53 target Ppm1d)
- p53 suppresses transposable elements and its inactivation leads to retrotransposition (Gudkov, Abrams)
- p53 can promote survival in some circumstances (Vousden)



Decade 5


Unanswered questions and therapeutic opportunities

p53 can be activated by a wide variety of triggers




The p53 transcriptional network

- It is now clear that p53 controls many genes that are linked to a wide range of biological processes
- Some are cell intrinsic and others cell extrinsic'
- p53 likely acts through coordination of multiple anti-proliferative programs
- Did this evolve to suppress cancer or other processes?








Context, context, context




- p53 likely coordinates a tumor suppressive program through multiple effectors
- Some may be more or less dependent on context
- Contextual factors include tissue type, activating stimulus and the presence of other oncogenic events
- What dictates context in p53 output?
- Can contextual functions of p53 be exploited?

A role for p53 in wound healing responses?



A role for p53 in wound healing responses?

Oil Red O staining of livers post-damage



Humpton Cell Death Diff 2022

p53 action in wound healing is intriguing

Cancer: A wound that does not heal

HISTOLOGICAL SIMILARITIES

- Cancers often arise at sites of wounds
- Both involve inflammation, blood clotting factors, blood vessel formation, cell plasticity
- Both require tissue remodeling and cell proliferation

CELL AND MOLECULAR SIMILARITIES

- Overlapping changes in cell composition and cell state in the tissue
- Critical role for stem cells and regenerative programs
- Molecular pathways important in wound healing are mutated in cancer

SEMINARS IN MEDICINE
OF THE
BETH ISRAEL HOSPITAL, BOSTON




JEFFREY S. FLIER, M.D., *Editor*
LISA H. UNDERHILL, *Assistant Editor*

TUMORS: WOUNDS THAT DO NOT HEAL
Similarities between Tumor Stroma Generation
and Wound Healing


HAROLD F. DVORAK, M.D.

p53 as 'guardian of the genome'

Fluorescence reporter to identify cells that sporadically inactivate p53




Schematic of copy number evolution following p53 inactivation




p53 and immune modulation

- Emerging evidences suggests p53 directly controls immune surveillance functions
- p53 directly regulates factors that are important for NK and T cell surveillance
- Consistent with a role for p53 in limiting viral responses



p53 and immune modulation


- Emerging evidences suggests p53 directly controls immune surveillance functions
- p53 directly regulates factors that are important for NK and T cell surveillance
- Consistent with a role for p53 in limiting viral responses
- **Reactivation of endogenous p53 in tumors can provoke immune mediated cancer regressions**
- **p53 can coordinate cell intrinsic and extrinsic tumor suppression**



Chen, Cancer Discovery 2022

Therapeutic opportunities for targeting p53 (p53 wild-type tumors)


- p53 activation in tumors by chemotherapy can be potently tumor suppressive
- Agents in clinical trials that disrupt the Mdm2-p53 (or mdmx-p53) interactions - will they be too toxic?
- *Can p53 inhibitors be useful for certain indications (ischemic injury, neurodegeneration)?*



Therapeutic opportunities for targeting p53 (p53 wild-type tumors)

FIGURE. Reactivation of p53 Pathway¹


Reactivation of p53 pathway is achieved through Nutlin-3a. With oncogenic activation, the ARF protein interacts with MDM2 sequestering it into the nucleolus, which prevents the proteasomal degradation of p53 that activates its target genes promoting apoptosis, growth arrest, DNA repair, and senescence.



- Small molecule inhibitors of Mdm2 and/or MdmX (e.g. Nutlin) can effectively reengage p53
- Drugs do not work in p53 null cells (i.e. specific)
- Many clinical trials have been performed showing limited efficacy and toxicities
- Drugs can cause thrombocytopenia, gastrointestinal issues, and clonal expansion of p53 mutant cells


Therapeutic opportunities for targeting p53

(p53 mutant tumors)



- Synthetic lethality exploits vulnerabilities created by specific cancer mutations.
- Example: PARP inhibitors targeting BRCA-mutant cancers.
- Functional genomics screens enable systematic identification of synthetic lethal partners.
- Unfortunately, synthetic lethal strategies have largely been unsuccessful for *TP53* mutations.

Therapeutic opportunities for targeting p53 (p53 mutant tumors)




Alan Fersht

- Developed rezatapopt, a small molecule that stabilizes TP53 Y220C mutant p53 and restores wild-type conformation and DNA binding.
- Reactivated the p53 transcriptional program, inducing canonical targets (e.g., p21, MDM2), causing G1 arrest.
- Selectively inhibited growth of Y220C-mutant tumors and suppressed xenograft growth in vivo.
- Demonstrates that mutation-specific pharmacologic reactivation of mutant p53 is therapeutically viable.


Saturation mutagenesis reveals insights into the fitness of *TP53* mutations

a





- CRISPR saturation genome editing generated ~9,200 *TP53* variants to measure mutation function in human cells.
- Most cancer-associated *TP53* missense mutations cause loss or partial loss of tumor-suppressor activity.
- CRISPR scanning reveals subtle dysfunction—including protein destabilization and splicing defects—missed by cDNA screens.
- Revealed clinically-actionable alleles: stabilization of partial LOF with small molecules or ASO that correct mutations the alter splicing

Therapeutic opportunities for targeting p53 (p53 mutant tumors)



Mutant p53 mislocalizes PLK4



HCT116^{y220C}



PLK4

centrosomes

HC1116^{p53^{-/-}}



PLK4 localizes



to centrosomes

Sadagopan A. et al., *Nature Chemical Biology* (2025). doi: 10.1038/s41589-025-02051-7

- Missense *TP53* mutations lead to a stabilized p53 but inactive protein
- Bifunctional molecules tether mutant p53 to PLK4.
- PLK4 is mislocalized from centrosomes, blocking centrosome duplication.
- Mitotic failure selectively kills TP53-mutant cells.

Therapeutic opportunities for targeting p53

(p53 mutant tumors)





- p53 mimicry aims to activate downstream p53 effector programs despite p53 loss.
- p53 reactivation rewires metabolism, increasing α -ketoglutarate (α KG) and promoting differentiation programs.
- Suppressing the α KG dehydrogenase subunit (OGDH) elevates α KG and induces differentiation even without p53.
- OGDH inhibition could mimic p53 signaling, but potential toxicity remains a concern.

uPAR marks a unique state and niche in premalignancy that expands in cancer

Pre-tumor (p53 intact)


Tumor (p53 lost)




GFP (p53 intact) HMGA2 (progenitor) TNC (activated myCAF) ARG1 (suppressive myeloid) uPAR

CAR T cells targeting uPAR ablate p53 mutant ovarian tumors

uPAR-positive ovarian cancer xenograft



uPAR CAR T cells response



$[^{89}\text{Zr}]Zr\text{-DFO-h.uPAR}$



Edwin
Pratt



Jason
Lewis

Pratt, et al. All rights reserved.

‘All models are wrong, but some are useful’

–George Box

'All models are wrong, but some are useful'

-George Box

'All models are wrong, it just a matter of how wrong'

-p53 researcher